Novel pyrimidines as antitubercular agents

Daigo Inoyama, Steven D. Paget, Riccardo Russo, Srinivasan Kandasamy, Pradeep Kumar, Eric Singleton, James Occi, Margareta Tuckman, Matthew D. Zimmerman, Hsin Pin Ho, Alexander L. Perryman, Véronique Dartois, Nancy Connell, Joel S. Freundlicha

Research output: Contribution to journalArticle

Abstract

Mycobacterium tuberculosis infection is responsible for a global pandemic. New drugs are needed that do not show cross-resistance with the existing front-line therapeutics. A triazine antitubercular hit led to the design of a related pyrimidine family. The synthesis of a focused series of these analogs facilitated exploration of their in vitro activity, in vitro cytotoxicity, and physiochemical and absorption-distribution-metabolism-excretion properties. Select pyrimidines were then evaluated for their pharmacokinetic profiles in mice. The findings suggest a rationale for the further evolution of this promising series of antitubercular small molecules, which appear to share some similarities with the clinical compound PA-824 in terms of activation, while highlighting more general guidelines for the optimization of small-molecule antitubercular agents.

Original languageEnglish (US)
Article numbere02063-1
JournalAntimicrobial agents and chemotherapy
Volume62
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Antitubercular Agents
Pyrimidines
Triazines
Mycobacterium Infections
Pandemics
Mycobacterium tuberculosis
Pharmacokinetics
Guidelines
Pharmaceutical Preparations
In Vitro Techniques
Therapeutics
2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo(2,1-b)(1,3)oxazine
pyrimidine

Keywords

  • Antitubercular
  • Mycobacterium tuberculosis
  • Pharmacokinetics
  • Pyrimidine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Inoyama, D., Paget, S. D., Russo, R., Kandasamy, S., Kumar, P., Singleton, E., ... Freundlicha, J. S. (2018). Novel pyrimidines as antitubercular agents. Antimicrobial agents and chemotherapy, 62(3), [e02063-1]. https://doi.org/10.1128/AAC.02063-17

Novel pyrimidines as antitubercular agents. / Inoyama, Daigo; Paget, Steven D.; Russo, Riccardo; Kandasamy, Srinivasan; Kumar, Pradeep; Singleton, Eric; Occi, James; Tuckman, Margareta; Zimmerman, Matthew D.; Ho, Hsin Pin; Perryman, Alexander L.; Dartois, Véronique; Connell, Nancy; Freundlicha, Joel S.

In: Antimicrobial agents and chemotherapy, Vol. 62, No. 3, e02063-1, 01.03.2018.

Research output: Contribution to journalArticle

Inoyama, D, Paget, SD, Russo, R, Kandasamy, S, Kumar, P, Singleton, E, Occi, J, Tuckman, M, Zimmerman, MD, Ho, HP, Perryman, AL, Dartois, V, Connell, N & Freundlicha, JS 2018, 'Novel pyrimidines as antitubercular agents', Antimicrobial agents and chemotherapy, vol. 62, no. 3, e02063-1. https://doi.org/10.1128/AAC.02063-17
Inoyama D, Paget SD, Russo R, Kandasamy S, Kumar P, Singleton E et al. Novel pyrimidines as antitubercular agents. Antimicrobial agents and chemotherapy. 2018 Mar 1;62(3). e02063-1. https://doi.org/10.1128/AAC.02063-17
Inoyama, Daigo ; Paget, Steven D. ; Russo, Riccardo ; Kandasamy, Srinivasan ; Kumar, Pradeep ; Singleton, Eric ; Occi, James ; Tuckman, Margareta ; Zimmerman, Matthew D. ; Ho, Hsin Pin ; Perryman, Alexander L. ; Dartois, Véronique ; Connell, Nancy ; Freundlicha, Joel S. / Novel pyrimidines as antitubercular agents. In: Antimicrobial agents and chemotherapy. 2018 ; Vol. 62, No. 3.
@article{5f7426bf32724668b11f366faad5f4b8,
title = "Novel pyrimidines as antitubercular agents",
abstract = "Mycobacterium tuberculosis infection is responsible for a global pandemic. New drugs are needed that do not show cross-resistance with the existing front-line therapeutics. A triazine antitubercular hit led to the design of a related pyrimidine family. The synthesis of a focused series of these analogs facilitated exploration of their in vitro activity, in vitro cytotoxicity, and physiochemical and absorption-distribution-metabolism-excretion properties. Select pyrimidines were then evaluated for their pharmacokinetic profiles in mice. The findings suggest a rationale for the further evolution of this promising series of antitubercular small molecules, which appear to share some similarities with the clinical compound PA-824 in terms of activation, while highlighting more general guidelines for the optimization of small-molecule antitubercular agents.",
keywords = "Antitubercular, Mycobacterium tuberculosis, Pharmacokinetics, Pyrimidine",
author = "Daigo Inoyama and Paget, {Steven D.} and Riccardo Russo and Srinivasan Kandasamy and Pradeep Kumar and Eric Singleton and James Occi and Margareta Tuckman and Zimmerman, {Matthew D.} and Ho, {Hsin Pin} and Perryman, {Alexander L.} and V{\'e}ronique Dartois and Nancy Connell and Freundlicha, {Joel S.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1128/AAC.02063-17",
language = "English (US)",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Novel pyrimidines as antitubercular agents

AU - Inoyama, Daigo

AU - Paget, Steven D.

AU - Russo, Riccardo

AU - Kandasamy, Srinivasan

AU - Kumar, Pradeep

AU - Singleton, Eric

AU - Occi, James

AU - Tuckman, Margareta

AU - Zimmerman, Matthew D.

AU - Ho, Hsin Pin

AU - Perryman, Alexander L.

AU - Dartois, Véronique

AU - Connell, Nancy

AU - Freundlicha, Joel S.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Mycobacterium tuberculosis infection is responsible for a global pandemic. New drugs are needed that do not show cross-resistance with the existing front-line therapeutics. A triazine antitubercular hit led to the design of a related pyrimidine family. The synthesis of a focused series of these analogs facilitated exploration of their in vitro activity, in vitro cytotoxicity, and physiochemical and absorption-distribution-metabolism-excretion properties. Select pyrimidines were then evaluated for their pharmacokinetic profiles in mice. The findings suggest a rationale for the further evolution of this promising series of antitubercular small molecules, which appear to share some similarities with the clinical compound PA-824 in terms of activation, while highlighting more general guidelines for the optimization of small-molecule antitubercular agents.

AB - Mycobacterium tuberculosis infection is responsible for a global pandemic. New drugs are needed that do not show cross-resistance with the existing front-line therapeutics. A triazine antitubercular hit led to the design of a related pyrimidine family. The synthesis of a focused series of these analogs facilitated exploration of their in vitro activity, in vitro cytotoxicity, and physiochemical and absorption-distribution-metabolism-excretion properties. Select pyrimidines were then evaluated for their pharmacokinetic profiles in mice. The findings suggest a rationale for the further evolution of this promising series of antitubercular small molecules, which appear to share some similarities with the clinical compound PA-824 in terms of activation, while highlighting more general guidelines for the optimization of small-molecule antitubercular agents.

KW - Antitubercular

KW - Mycobacterium tuberculosis

KW - Pharmacokinetics

KW - Pyrimidine

UR - http://www.scopus.com/inward/record.url?scp=85042412222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042412222&partnerID=8YFLogxK

U2 - 10.1128/AAC.02063-17

DO - 10.1128/AAC.02063-17

M3 - Article

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

M1 - e02063-1

ER -